- Pharmaceutical companies
- North America
- United States
- Amneal Pharmaceuticals
Amneal Pharmaceuticals in United States
E-mail: MediaRelations@amneal.com, Invest@amneal.com
Web: https://amneal.com/contact/
Address:
-
Amneal U.S. Corporate Offices
400 Crossing Boulevard, 3rd Floor Bridgewater, New Jersey 08807
Phone: +1 908-947-3120
Fax: (908) 947-3146
Other Amneal Pharmaceuticals's locations around the world
Clinical Trials sponsored by Amneal Pharmaceuticals
-
Amneal Pharmaceuticals, LLCBefejezveMenopauza okozta atrófiás hüvelygyulladásEgyesült Államok
-
Amneal Pharmaceuticals, LLCSymbio, LLCBefejezveKomplikációmentes húgyúti fertőzésekEgyesült Államok
-
Amneal Pharmaceuticals, LLCCBCC Global Inc.; Amneal EU, LimitedMég nincs toborzásSzemészeti hipertónia | Nyitott zugú glaukómaEgyesült Államok
-
Amneal Pharmaceuticals Co. India Private LimitedBefejezve
-
Amneal Pharmaceuticals, LLCCBCC Global ResearchToborzásSzemészeti hipertónia | Glaukóma, nyitott szögEgyesült Államok
-
Amneal Pharmaceuticals, LLCNovum Pharmaceutical Research ServicesBefejezveSzezonális allergiás rhinitisEgyesült Államok
-
Amneal Pharmaceuticals, LLCPhase One Solutions, Inc.BefejezveHipogonadotrop hipogonadizmus | Elsődleges hipogonadizmusEgyesült Államok
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Befejezve
-
Amneal Pharmaceuticals, LLCSristek Clinical Research Solutions LimitedBefejezve
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Ismeretlen
About Amneal Pharmaceuticals
Amneal's Generics Division focuses on a broad range of therapeutic areas, including solid oral dosage products and alternative dosage form products. The company's Specialty Pharma Division is focused on the development of proprietary branded pharmaceutical products for the treatment of Central Nervous System disorders, Endocrine disorders and other select specialty segments. This division commercializes several branded pharmaceutical products, including Rytary, an extended release oral capsule formulation for the treatment of Parkinson's disease, Unithroid, for treatment of hypothyroidism, Emverm, for treatment of certain gastrointestinal infections, and Zomig Nasal Spray, for the acute treatment of migraines. As of July 2019, the company owned ten manufacturing sites and seven R&D sites in the United States, Ireland and India. In 2020, in response to the interest in chloroquine and hydroxychloroquine during the COVID-19 pandemic, and before the United States Food and Drug Administration's emergency use authorization was withdrawn, Amneal ramped up production. In June 2023, the US FDA declined to approve a drug (carbidopa-levodopa) designed to help control symptoms in Parkinson's disease patients for a longer duration, because of inadequate safety data